Modernes Management der chronischen Rhinosinusitis

Mit dem Einzug der Biologika-Therapie in die Behandlung der chronischen Rhinosinusitis (CRS) während der letzten Jahre ergeben sich weitreichende Neuerungen des Managements der Erkrankung. Vor diesem Hintergrund bietet dieser Beitrag einen generellen Überblick über die konservativen und operativen Therapieschritte der modernen Behandlung der chronischen Rhinosinusitis.

Abstract

Chronic rhinosinusitis is a common disease. Due to the significant reduction of the quality of life, possible serious complications and economic consequences, a sufficient therapy is essential. With the entry of biologics into the treatment of chronic rhinosinusitis, relevant innovations have emerged in recent years. This article is aimed at providing an up-to-date overview of the conservative and surgical treatment options for chronic rhinosinusitis.

Kernaussagen

• Wegen der Einschränkung der Lebensqualität, sozioökonomischer Folgen und drohender Komplikationen ist die adäquate Therapie der CRS essenziell.

• Erstlinientherapie ist eine angemessene medikamentöse Therapie (AMT) bestehend aus topischen Glukokortikoiden und Nasenspülungen.

• Bei unzureichender Besserung unter AMT sollte die Indikation zur chirurgischen Therapie geprüft werden – in Einzelfällen auch zur oralen Glukokortikoidtherapie.

• Bei schwerer CRScNP ist die (mehrfache) chirurgische Therapie gegenüber der Biologika-Therapie abzuwägen.

Schlüsselwörter

chronische Rhinosinusitis - nasale Polyposis - Überblick

Keywords

chronic rhinosinusitis - nasal polyps - overview

Publication History

Article published online:
11 June 2024

• Literatur

• 1 Stuck BA, Beule A, Jobst D. et al. Guideline for “rhinosinusitis”-long version: S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery. HNO 2018; 66: 38-74 DOI: 10.1007/s00106-017-0401-5. (PMID: 28861645)
• 2 Beule A. Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden. GMS Curr Top Otorhinolaryngol Head Neck Surg 2015; 14: Doc11 DOI: 10.3205/cto000126. (PMID: 26770285)
• 3 Fokkens WJ, Lund VJ, Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58 (Suppl. 29) 1-464 DOI: 10.4193/Rhin20.600. (PMID: 32077450)
• 4 Helman SN, Barrow E, Edwards T. et al. The role of allergic rhinitis in chronic rhinosinusitis. Immunol Allergy Clin North Am 2020; 40: 201-214 DOI: 10.1016/j.iac.2019.12.010. (PMID: 32278445)
• 5 Tan BK, Schleimer RP, Kern RC. Perspectives on the etiology of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2010; 18: 21-26 DOI: 10.1097/MOO.0b013e3283350053. (PMID: 19966566)
• 6 Lee K, Tai J, Lee SH. et al. Advances in the knowledge of the underlying airway remodeling mechanisms in chronic rhinosinusitis based on the endotypes: a review. Int J Mol Sci 2021; 22: 910 DOI: 10.3390/ijms22020910. (PMID: 33477617)
• 7 Fokkens WJ, Lund V, Bachert C. et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019; 74: 2312-2319 DOI: 10.1111/all.13875. (PMID: 31678040)
• 8 Oykhman P, Paramo FA, Bousquet J. et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. J Allergy Clin Immunol 2022; 149: 1286-1295 DOI: 10.1016/j.jaci.2021.09.009.
• 9 Mosges R, Heubach CP. What is the evidence for non-antibiotic drug therapy of Rhinosinusitis?. Laryngorhinootologie 2011; 90: 740-746 DOI: 10.1055/s-0031-1285922. (PMID: 22016266)
• 10 Chong LY, Head K, Hopkins C. et al. Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4: CD011996 DOI: 10.1002/14651858.CD011996.pub2. (PMID: 27115217)
• 11 Stjarne P, Olsson P, Alenius M. Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2009; 135: 296-302 DOI: 10.1001/archoto.2009.2. (PMID: 19289710)
• 12 Wei CC, Adappa ND, Cohen NA. Use of topical nasal therapies in the management of chronic rhinosinusitis. Laryngoscope 2013; 123: 2347-2359 DOI: 10.1002/lary.24066. (PMID: 23553558)
• 13 Head K, Chong LY, Hopkins C. et al. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 2016; 4: CD011991 DOI: 10.1002/14651858.CD011991.pub2. (PMID: 27113367)
• 14 Rice JB, White AG, Scarpati LM. et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther 2017; 39: 2216-2229 DOI: 10.1016/j.clinthera.2017.09.011. (PMID: 29055500)
• 15 Simmonds JC, Paz-Lansberg M, Scangas G. et al. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results. Int Forum Allergy Rhinol 2022; 12: 257-265 DOI: 10.1002/alr.22886. (PMID: 34510786)
• 16 Deal RT, Kountakis SE. Significance of nasal polyps in chronic rhinosinusitis: symptoms and surgical outcomes. Laryngoscope 2004; 114: 1932-1935 DOI: 10.1097/01.mlg.0000147922.12228.1f. (PMID: 15510016)
• 17 Hopkins C, Slack R, Lund V. et al. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope 2009; 119: 2459-2465 DOI: 10.1002/lary.20653.
• 18 Mendelsohn D, Jeremic G, Wright ED. et al. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol 2011; 120: 162-166 DOI: 10.1177/000348941112000304. (PMID: 21510141)
• 19 Pfaar O, Beule AG, Laudien M. et al. Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM). HNO 2023; 71: 256-263 DOI: 10.1007/s00106-023-01273-2.
• 20 Bachert C, Han JK, Desrosiers M. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-1650 DOI: 10.1016/S0140-6736(19)31881-1.
• 21 Bachert C, Sousa AR, Lund VJ. et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol 2017; 140: 1024-1031.e14 DOI: 10.1016/j.jaci.2017.05.044.
• 22 Gevaert P, Omachi TA, Corren J. et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146: 595-605 DOI: 10.1016/j.jaci.2020.05.032. (PMID: 32524991)